🇺🇸 FDA
Patent

US 9669069

Use of a VEGF antagonist to treat angiogenic eye disorders

granted A61KA61K2039/505A61K38/179

Quick answer

US patent 9669069 (Use of a VEGF antagonist to treat angiogenic eye disorders) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K38/179, A61K9/0048, A61P